Antibody therapy of cancer. Review uri icon

Overview

abstract

  • The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.

publication date

  • March 22, 2012

Research

keywords

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Neoplasms

Identity

Scopus Document Identifier

  • 84858785688

Digital Object Identifier (DOI)

  • 10.1038/nrc3236

PubMed ID

  • 22437872

Additional Document Info

volume

  • 12

issue

  • 4